Table 3.

Association of 12 prostate cancer predisposition SNPs with prostate cancer recurrence after prostatectomy for clinically localized prostate cancer, Consortium on genetic risk of metastatic and recurrent prostate cancer

SNPGeneAlleleJHUFHCRCU PennMCCSummarySummary
RR (95% CI)*RR (95% CI)RR (95% CI)RR (95% CI)RR (95% CI)RR (95% CI)
Caucasians onlyAll study participants
rs10486567JAZF1C/T1.02 (0.82–1.26)1.16 (0.81–1.68)0.94 (0.67–1.33)1.18 (0.88–1.58)1.06 (0.91–1.24)1.13 (0.96–1.32)
rs1089644911q13G/A1.07 (0.88–1.30)0.76 (0.56–1.06)1.13 (0.86–1.49)1.03 (0.79–1.34)1.02 (0.88–1.18)0.95 (0.83–1.10)
rs10993994MSMBC/T0.95 (0.79–1.14)1.13 (0.83–1.55)1.02 (0.77–1.36)1.15 (0.91–1.44)1.02 (0.91–1.14)1.04 (0.92–1.18)
rs1277172810q23T/C0.93 (0.76–1.13)1.10 (0.80–1.50)1.09 (0.80–1.48)1.14 (0.90–1.46)1.05 (0.93–1.17)1.07 (0.93–1.23)
rs4072111IL16C/T1.28 (0.91–1.78)1.34 (0.85–1.98)0.83 (0.48–1.45)1.05 (0.70–1.58)1.14 (0.89–1.46)1.08 (0.87–1.34)
rs42423828q24G/A0.86 (0.65–1.14)1.27 (0.86–1.85)1.60 (1.12–2.29)1.08 (0.79–1.49)1.15 (0.83–1.58)1.14 (0.96–1.35)
rs4430796HNF1BT/C0.99 (0.83–1.18)0.90 (0.68–1.24)1.11 (0.83–1.47)1.01 (0.80–1.28)0.99 (0.89–1.11)1.00 (0.88–1.14)
rs4782726CDH13G/A1.08 (0.85–1.38)1.01 (0.72–1.50)0.62 (0.39–0.99)0.94 (0.70–1.25)0.92 (0.77–1.11)0.94 (0.80–1.12)
rs4961199CPNE3G/A1.10 (0.83–1.45)1.14 (0.77–1.72)1.13 (0.84–1.53)1.15 (0.92–1.44)1.09 (0.89–1.32)
rs4962416CTBP2A/G0.93 (0.77–1.13)0.98 (0.69–1.37)1.02 (0.76–1.37)1.18 (0.86–1.61)0.96 (0.86–1.07)0.91 (0.74–1.12)
rs69820808p21G/T0.95 (0.78–1.16)0.84 (0.61–1.14)1.11 (0.83–1.48)0.96 (0.74–1.24)0.96 (0.85–1.09)0.96 (0.84–1.10)
rs69832678q24G/T0.97 (0.80–1.17)0.91 (0.66–1.29)1.11 (0.81–1.52)0.73 (0.56–0.95)0.93 (0.80–1.08)0.91 (0.79–1.06)

NOTE: All I2 statistics were <20%, indicating no strong evidence of heterogeneity among studies.

  • *RR per risk allele assuming a log-additive model, estimated by conditional logistic regression; cases and controls (incidence density sampled) matched on age at radical prostatectomy, race, pathological stage and grade.

  • †RR per risk allele assuming a log-additive model, adjusted for age at radical prostatectomy, race, pathological stage, and grade.

  • †The summary RR and 95% CIs were calculated using a random-effects model, based on Caucasians only.

  • The summary RRs and 95% CIs were calculated using a random-effects model, based on all study populations.